NASDAQ : VIVS
VivoSim Labs, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.1577 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.62M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.56M |
| Enterprise Value | 1.21M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 16.59M |
| Shares Outstanding | 16.59M |
| Shares Change (YoY) | +83.42% |
| Shares Change (QoQ) | +98.74% |
| Owned by Insiders (%) | 2.61% |
| Owned by Institutions (%) | 0.69% |
| Float | 16.15M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 22.90 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 10.81 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.70 |
| Quick Ratio | 0.90 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -944.25 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -343.10% |
| Return on Assets (ROA) | -89.50% |
| Return on Invested Capital (ROIC) | -170.03% |
| Return on Capital Employed (ROCE) | -579.89% |
| Weighted Average Cost of Capital (WACC) | 11.41% |
| Revenue Per Employee | $7,467 |
| Profits Per Employee | -$822,533 |
| Employee Count | 15 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 5,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.49 |
| 52-Week Price Change | -93.28% |
| 50-Day Moving Average | 0.22 |
| 200-Day Moving Average | 1.07 |
| Relative Strength Index (RSI) | 36.06 |
| Average Volume (20 Days) | 1,034,824 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 598,424 |
| Short Previous Month | 707,866 |
| Short % of Shares Out | 3.61% |
| Short % of Float | 3.70% |
| Short Ratio (days to cover) | 0.58 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 112,000 |
| Gross Profit | -4.21M |
| Operating Income | -11.33M |
| Pretax Income | -12.33M |
| Net Income | -12.34M |
| EBITDA | -11.14M |
| EBIT | -11.33M |
| Loss Per Share | -$3.77 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.67M |
| Total Debt | 316,000 |
| Net Cash | 1.35M |
| Net Cash Per Share | $0.08 |
| Equity (Book Value) | -2.35M |
| Book Value Per Share | -0.73 |
| Working Capital | 1.33M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -10.10M |
| Capital Expenditures | -23,000 |
| Depreciation & Amortization | 194,000 |
| Net Borrowing | -353,000 |
| Free Cash Flow | -10.12M |
| FCF Per Share | -$0.61 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -10,116.96% |
| Pretax Margin | -11,011.61% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -83.42% |
| Shareholder Yield | -83.42% |
| Earnings Yield | -2,438.86% |
| FCF Yield | -394.77% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Mar 21, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -138.8 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |